Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claude Desnuelle

Showing results (71-80 of 74) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 74 results.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|October 5, 2017
July 2017 ENCALS statement on edaravoneAmmar Al-Chalabi, Peter M Andersen, Siddharthan Chandran, et al.
Plos One|February 6, 2016
Gender as a Modifying Factor Influencing Myotonic Dystrophy Type 1 Phenotype Severity and Mortality: A Nationwide Multiple Databases Cross-Sectional Observational StudyCeline Dogan, Marie De Antonio, Dalil Hamroun, et al.
Lancet (London, England)|May 12, 2025
Efficacy and safety of low-dose IL-2 as an add-on therapy to riluzole (MIROCALS): a phase 2b, double-blind, randomised, placebo-controlled trialGilbert Bensimon, P Nigel Leigh, Timothy Tree, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|February 17, 2022
Clinical trials in pediatric ALS: a TRICALS feasibility studyTessa Kliest, Ruben P A Van Eijk, Ammar Al-Chalabi, et al.
Pageof 8

Showing results (71-80 of 74) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 74 results.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|October 5, 2017
July 2017 ENCALS statement on edaravoneAmmar Al-Chalabi, Peter M Andersen, Siddharthan Chandran, et al.
Plos One|February 6, 2016
Gender as a Modifying Factor Influencing Myotonic Dystrophy Type 1 Phenotype Severity and Mortality: A Nationwide Multiple Databases Cross-Sectional Observational StudyCeline Dogan, Marie De Antonio, Dalil Hamroun, et al.
Lancet (London, England)|May 12, 2025
Efficacy and safety of low-dose IL-2 as an add-on therapy to riluzole (MIROCALS): a phase 2b, double-blind, randomised, placebo-controlled trialGilbert Bensimon, P Nigel Leigh, Timothy Tree, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|February 17, 2022
Clinical trials in pediatric ALS: a TRICALS feasibility studyTessa Kliest, Ruben P A Van Eijk, Ammar Al-Chalabi, et al.
Pageof 8